Overview


According to FutureWise analysis the market for rare biomarkers specimen collection and stabilization in 2023 is US$ 27.64 billion, and is expected to reach US$ 54.76 billion by 2031 at a CAGR of 8.90%.

Biomarkers, also known as molecular markers or signature molecules, are used to assess the body's response to treatment. They also help in the examination of organ functions and other conditions. They are essential in imaging technology because they allow for clear imaging of cancer tumors and other issues. The market is being driven by a significant increase in research studies that examine the role of biomarkers in disease management. The market's revenue growth has been affected by factors such as the preference for non-invasive treatment of diseases and growing demand for personalized medicine. The number of research studies on this topic has increased dramatically over the last few years. This is a sign of the growing interest in rare biomarker specimen stabilization and collection by healthcare providers. Investments in clinical applications have also been driven by increasing evidence of the effectiveness of rare biomarkers for disease management. Liquid biopsy has been a key factor in the market dynamics for rare biomarker specimen collection. The primary growth factor in the market for rare biomarkers specimens and stabilization in clinical settings is liquid biopsies. The current liquid biopsy can only be used by patients with metastatic, advanced cancer. The clinical adoption of these tests is limited by regulatory hurdles and low reimbursement. The uptake of these tests will be driven by the availability of more data about their clinical utility. Liquid biopsy is only one aspect of the clinical space. Companies are involved in the development and commercialization of ccfDNA based NIPT. Investors have also provided significant capital inflow to help this segment grow in terms of test volume and revenue. Recent years have seen a rise in market competition due to the introduction of new assays like liquid biopsy assays, and the emergence microfluidic-based biomarker seperation technologies. This market will see increased competition due to new product launches and expanded applications. To gain an edge in the exosome isolating space, companies are entering into strategic agreements. Biopharmaceutical companies such as Roche or Amgen have partnered with liquid biopsy companies to develop companion diagnostics and speed up personalized medicine. Biopharma companies are expected to enter the market for rare biomarkers specimen collections and stabilization. This will increase competition among key stakeholders, including diagnostics developers as well as service providers.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Rare Biomarkers Specimen Collection and Stabilization Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Rare Biomarkers Specimen Collection and Stabilization Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Miltenyi Biotec
  • F.Hoffmann-La Roche Ltd
  • Qiagen
  • STRECK
  • CreatvMicroTech Inc
  • Genetix
  • Creative-Bioarray
  • Amgen Inc
  • Agena bioscience
  • Bio-rad Laboratories Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Circulating Cell Free DNA (ccfDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes/Extracellular Vesicles

By Product

  • Isolation Kits & Reagents
  • Blood Collection Tubes
  • Systems

By Distribution Channel

  • NIPT
  • Oncology
  • Research
  • Diagnostics
    • Screening
    • Treatment Monitoring
  • Transcriptomics
  • Pharmacogenomics
  • Transplant Rejection
  • Population Screening
  • Cardiovascular Diseases
  • Other Applications

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Rare Biomarkers Specimen Collection and Stabilization Market By Type, By Product, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Rare Biomarkers Specimen Collection and Stabilization Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Rare Biomarkers Specimen Collection and Stabilization Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Rare Biomarkers Specimen Collection and Stabilization Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Rare Biomarkers Specimen Collection and Stabilization Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Circulating Cell Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles

  • 8.   Rare Biomarkers Specimen Collection and Stabilization Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Isolation Kits & Reagents
        2. Blood Collection Tubes
        3. Systems

  • 9.   Rare Biomarkers Specimen Collection and Stabilization Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. NIPT
        2. Oncology
        3. Research
        4. Diagnostics
         4.1. Screening
         4.2. Treatment Monitoring
        5. Transcriptomics
        6. Pharmacogenomics
        7. Transplant Rejection
        8. Population Screening
        9. Cardiovascular Diseases
        10. Other Applications

  • 10.   North America Rare Biomarkers Specimen Collection and Stabilization Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Rare Biomarkers Specimen Collection and Stabilization Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Rare Biomarkers Specimen Collection and Stabilization Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Miltenyi Biotec
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. F.Hoffmann-La Roche Ltd
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Qiagen
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. STRECK
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. CreatvMicroTech Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Genetix
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Creative-Bioarray
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Amgen Inc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Agena bioscience
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Bio-rad Laboratories Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients